The aim of this study is to dertermine whether Survivin autoantibody could be used as a diagnostic factor of lung cancer and what the clinical value of Survivin autoantibody was in non-small cell lung cancer (NSCLC). This evidence concerns the gene BIRC5 and lung carcinoma.